APC and laryngotracheoesophageal cleft: However, sEPCR, which inhibits APC activity and has been reported as a marker associated with higher thrombotic risk (36), was 1.4-fold higher (p=0.0410) in the LC cohort compared to the Recovered cohort (Figure 5F).